Transparency notification UCB SA/NV

Brussels (Belgium), 30 March 2021 – 20:00 (CEST) – regulated information

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification.

The transparency notification dated 29 March 2021 has been submitted in accordance with Article 18 juncto Article 6 of the law of 2 May 2007 on the disclosure of large shareholdings, due to UCB covering its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group. As a result thereof, voting rights relating to voting securities held by UCB SA/NV crossed the 3% threshold on 24 March 2021. 

On 24 March 2021, UCB SA/NV owned 5 855 888 UCB shares with voting rights (versus 5 742 539 UCB shares in its previous notification dated 20 January 2020), representing 3.01% of the total number of shares issued by the company (194 505 658) (versus 2.95% in the notification dated 20 January 2020). 

2.  Content of the notification

• Reason for the notification: Acquisition or disposal of voting securities or voting rights
• Notification by: A parent undertaking or a controlling person.
• Person subject to the notification requirement: 

• Date on which the threshold is crossed: 24 March 2021
• Threshold crossed (in %): 3%
• Denominator: 194 505 658
• Notified details: 

• Chain of controlled undertakings through which the holding is effectively held: 

         UCB SA/NV indirectly controls UCB Fipar SA.•    

• Additional information: 

The disclosure obligation arose due to voting rights held by UCB SA crossing the 3% minimum threshold. The variation is due to UCB covering its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group. 

3.  Further information

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news